c-Met may be a biomarker for metastatic hepatocellular carcinoma
Tuesday, September 28, 2010 - 16:42
in Health & Medicine
Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.